Posts by: Alice Melão

News

Nanobiotix will soon initiate a Phase 1/2 trial of NBTXR3 in combination with an anti-PD-1 antibody — Bristol-Myers Squibb’s Opdivo (nivolumab) or Merck’s Keytruda (pembrolizumab) — in patients with advanced head and neck ... Read more

December 22, 2017December 22, 2017

Phase 1b Trial to Test TAR-200, Opdivo Combo as Treatment for Muscle Invasive Bladder Cancer

News

A new Phase 1b clinical trial will evaluate if combining TAR-200 (GemRIS), a chemotherapy-releasing agent, and Opdivo (nivolumab) is a safe, well tolerated, and efficacious approach for the treatment of muscle invasive ... Read more

December 21, 2017

Halting TGF-β Activity May Reduce Resistance to Checkpoint Inhibitors, Study Shows

News

An analysis of tumor samples collected during the IMvigor210 Phase 2 clinical trial has revealed a mechanism of cancer cell resistance to immune checkpoint inhibitors like Tecentriq (atezolizumab). The findings will help ... Read more

December 20, 2017

EMA’s CHMP Recommends Yervoy for Patients 12 and Older with Advanced Melanoma

News

Yervoy (ipilimumab) has received a positive review by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of unresectable or ... Read more

December 14, 2017

Genentech Combo Delays Kidney Cancer Progression, Phase 3 Trial Shows

News

A combination of the immunotherapies Tecentriq (atezolizumab) and Avastin (bevacizumab) increased the time it took kidney cancer to progress, compared with the standard treatment Sutent (sunitinib), a Phase 3 clinical trial shows. ... Read more

December 6, 2017

Bavencio Fails to Increase Survival of Advanced Gastric Cancer Patients in Phase 3 Trial

News

Bavencio (avelumab) failed to increase overall survival of unresectable, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma patients in a Phase 3 trial, Merck KGaA and Pfizer announced. The JAVELIN Gastric ... Read more

November 30, 2017

IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma

News

The U.S. Food and Drug Administration (FDA) granted fast track status to Idera Pharmaceuticals‘ IMO-2125, in combination with Yervoy (ipilimumab), for the treatment of metastatic melanoma patients whose disease progressed ... Read more

November 16, 2017November 16, 2017

Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma

News

Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer. Inovio Pharmaceuticals is leading the ... Read more

November 14, 2017November 14, 2017

Early Results Suggest Opdivo Combo May Help People with Advanced Pancreatic Cancer

News

Adding cabiralizumab to Opdivo (nivolumab) induced durable clinical benefit in heavily treated pancreatic cancer patients, a group largely insensitive to immunotherapy, early results from an ongoing Phase 1a/1b trial show. ... Read more

November 9, 2017November 9, 2017

FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN

News

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on Cellectis‘ Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), allowing the ... Read more